معرفی
Paul Young is a Professor of Commercialisation at Macquarie Business School and Professor of Respiratory Technology at the Woolcock Medical Research Institute, the globally leading institute for respiratory and sleep disease research. He specializes in commercialization, entrepreneurship, pharmaceutical innovation, and MedTech business creation. With over 25 years in academia and pharmaceutical sectors, he holds leadership roles in multidisciplinary programs like Sydney SPARK and Biodesign.Sydney, fostering medical device and therapeutic innovations.
Education:
- PhD in Pharmaceutics, University of Bath (2021)
- BSc (Hons) in Chemistry, University of the West of England (1996)
Research Focus: Paul’s work centers on aerosol chemistry, drug delivery systems (e.g., dry powder inhalers), and translational research in pharmaceuticals. He explores sustainable manufacturing techniques like 3D printing for drug devices and investigates therapies for lung cancer, cystic fibrosis, and neurodegenerative disorders using inhalation-based delivery. His research bridges academic discovery and commercial applications, emphasizing nanoparticle technology and clinical translation.
Key Projects (2019–2025):
- Targeting Cystic Fibrosis Using a Novel Inhalation Therapy (2021–2022)
- Unravelling the Mechanisms of Aerosolised Toxins (2020–2022)
- Engineering Better Sprays for Leaf Coating (2019–2022)
Leadership & Industry: As CEO of Ab Initio Pharma, he leads pharmaceutical R&D. He chairs the Inaugural Commercialization role at the University of Sydney and serves on boards of companies like Nanopharm UK and Pivot Innovations. His efforts have spawned spin-off companies and major pharma licensing deals.
Labs & Teams: Collaborates with cross-disciplinary teams at Woolcock Institute and Sydney’s medical innovation programs to advance therapeutic development and commercialization strategies.
